These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9441094)

  • 1. Bioavailability of Chinese rifapentine during a clinical trial in Hong Kong.
    Tam CM; Chan SL; Lam CW; Dickinson JM; Mitchison DA
    Int J Tuberc Lung Dis; 1997 Oct; 1(5):411-6. PubMed ID: 9441094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures.
    Tam CM; Chan SL; Kam KM; Goodall RL; Mitchison DA
    Int J Tuberc Lung Dis; 2002 Jan; 6(1):3-10. PubMed ID: 11931398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of rifapentine: the way ahead.
    Mitchison DA
    Int J Tuberc Lung Dis; 1998 Aug; 2(8):612-5. PubMed ID: 9712273
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA approves rifapentine for the treatment of pulmonary tuberculosis.... Food and Drug Administration.
    Roehr B
    J Int Assoc Physicians AIDS Care; 1998 Aug; 4(8):19-25. PubMed ID: 11365728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rifapentine for the treatment of pulmonary tuberculosis.
    Munsiff SS; Kambili C; Ahuja SD
    Clin Infect Dis; 2006 Dec; 43(11):1468-75. PubMed ID: 17083024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single and multiple dose pharmacokinetics of rifapentine in man: part II.
    Keung A; Eller MG; McKenzie KA; Weir SJ
    Int J Tuberc Lung Dis; 1999 May; 3(5):437-44. PubMed ID: 10331734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of two long-acting rifamycins, rifapentine and FCE 22807, in experimental murine tuberculosis.
    Dhillon J; Dickinson JM; Guy JA; Ng TK; Mitchison DA
    Tuber Lung Dis; 1992 Apr; 73(2):116-23. PubMed ID: 1643297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment.
    Bock NN; Sterling TR; Hamilton CD; Pachucki C; Wang YC; Conwell DS; Mosher A; Samuels M; Vernon A;
    Am J Respir Crit Care Med; 2002 Jun; 165(11):1526-30. PubMed ID: 12045127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rifapentine--a long-acting rifamycin for tuberculosis.
    Med Lett Drugs Ther; 1999 Feb; 41(1047):21-2. PubMed ID: 10076594
    [No Abstract]   [Full Text] [Related]  

  • 10. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis.
    Sirgel FA; Fourie PB; Donald PR; Padayatchi N; Rustomjee R; Levin J; Roscigno G; Norman J; McIlleron H; Mitchison DA
    Am J Respir Crit Care Med; 2005 Jul; 172(1):128-35. PubMed ID: 15805182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy.
    Weiner M; Bock N; Peloquin CA; Burman WJ; Khan A; Vernon A; Zhao Z; Weis S; Sterling TR; Hayden K; Goldberg S;
    Am J Respir Crit Care Med; 2004 Jun; 169(11):1191-7. PubMed ID: 14962821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzyme induction observed in healthy volunteers after repeated administration of rifapentine and its lack of effect on steady-state rifapentine pharmacokinetics: part I.
    Keung A; Reith K; Eller MG; McKenzie KA; Cheng L; Weir SJ
    Int J Tuberc Lung Dis; 1999 May; 3(5):426-36. PubMed ID: 10331733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The development of a standardised screening protocol for the in vivo assessment of rifampicin bioavailability.
    McIlleron H; Gabriels G; Smith PJ; Fourie PB; Ellard GA
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S329-35; discussion S351-2. PubMed ID: 10593713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does AIDS impair the absorption of antituberculosis agents?
    Taylor B; Smith PJ
    Int J Tuberc Lung Dis; 1998 Aug; 2(8):670-5. PubMed ID: 9712282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market.
    Pillai G; Fourie PB; Padayatchi N; Onyebujoh PC; McIlleron H; Smith PJ; Gabriels G
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S309-16; discussion S317-21. PubMed ID: 10593710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers.
    Dooley KE; Savic RM; Park JG; Cramer Y; Hafner R; Hogg E; Janik J; Marzinke MA; Patterson K; Benson CA; Hovind L; Dorman SE; Haas DW;
    Antimicrob Agents Chemother; 2015; 59(6):3399-405. PubMed ID: 25824215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rifapentine: its role in the treatment of tuberculosis.
    Temple ME; Nahata MC
    Ann Pharmacother; 1999 Nov; 33(11):1203-10. PubMed ID: 10573321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [In vitro study on cross resistance of rifampin and rifapentine for Mycobacterium tuberculosis].
    Duanmu HJ; Liu YH; Jiang GL; Wang SM; Fu YH
    Zhonghua Jie He He Hu Xi Za Zhi; 2005 Mar; 28(3):192-4. PubMed ID: 15854417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition and metabolism of 14C-rifapentine in healthy volunteers.
    Reith K; Keung A; Toren PC; Cheng L; Eller MG; Weir SJ
    Drug Metab Dispos; 1998 Aug; 26(8):732-8. PubMed ID: 9698286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of rifapentine in children.
    Blake MJ; Abdel-Rahman SM; Jacobs RF; Lowery NK; Sterling TR; Kearns GL
    Pediatr Infect Dis J; 2006 May; 25(5):405-9. PubMed ID: 16645503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.